Teladoc (TDOC) Shares Sold by Eagle Asset Management Inc.

Eagle Asset Management Inc. decreased its position in Teladoc (NYSE:TDOC) by 0.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,433,132 shares of the health services provider’s stock after selling 16,768 shares during the quarter. Eagle Asset Management Inc. owned about 3.90% of Teladoc worth $98,055,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in TDOC. Carillon Tower Advisers Inc. acquired a new stake in shares of Teladoc in the fourth quarter valued at $57,973,000. Global Thematic Partners LLC acquired a new stake in shares of Teladoc in the first quarter valued at $51,465,000. Champlain Investment Partners LLC acquired a new stake in shares of Teladoc in the fourth quarter valued at $29,290,000. Alliancebernstein L.P. lifted its holdings in shares of Teladoc by 15.7% in the fourth quarter. Alliancebernstein L.P. now owns 4,472,612 shares of the health services provider’s stock valued at $155,871,000 after buying an additional 607,002 shares during the period. Finally, Bamco Inc. NY lifted its holdings in shares of Teladoc by 32.7% in the fourth quarter. Bamco Inc. NY now owns 1,931,500 shares of the health services provider’s stock valued at $67,313,000 after buying an additional 475,600 shares during the period.

Get Teladoc alerts:

Several brokerages have recently weighed in on TDOC. SunTrust Banks upped their price objective on Teladoc to $48.00 and gave the company a “positive” rating in a report on Wednesday, May 2nd. Craig Hallum set a $39.00 price objective on Teladoc and gave the company a “hold” rating in a report on Wednesday, May 2nd. ValuEngine upgraded Teladoc from a “buy” rating to a “strong-buy” rating in a report on Wednesday, May 2nd. Canaccord Genuity restated a “buy” rating and issued a $45.00 price objective on shares of Teladoc in a report on Friday, April 13th. Finally, Wells Fargo set a $46.00 target price on Teladoc and gave the company a “buy” rating in a report on Friday, April 6th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $42.67.

Shares of Teladoc opened at $48.70 on Friday, according to Marketbeat. Teladoc has a 12 month low of $49.10 and a 12 month high of $49.75. The firm has a market cap of $3.06 billion, a PE ratio of -29.52 and a beta of 0.35. The company has a debt-to-equity ratio of 0.38, a current ratio of 4.15 and a quick ratio of 4.15.

Teladoc (NYSE:TDOC) last announced its earnings results on Tuesday, May 1st. The health services provider reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.04. The business had revenue of $89.64 million during the quarter, compared to the consensus estimate of $86.77 million. Teladoc had a negative return on equity of 20.40% and a negative net margin of 41.06%. Teladoc’s revenue was up 109.0% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.30) earnings per share. research analysts anticipate that Teladoc will post -1.37 earnings per share for the current fiscal year.

In related news, SVP Andrew Turitz sold 19,245 shares of the stock in a transaction dated Friday, March 2nd. The stock was sold at an average price of $39.25, for a total value of $755,366.25. Following the completion of the sale, the senior vice president now directly owns 16,700 shares of the company’s stock, valued at approximately $655,475. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Mark Hirschhorn sold 100,000 shares of the stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $39.60, for a total value of $3,960,000.00. Following the completion of the sale, the chief financial officer now directly owns 98,960 shares of the company’s stock, valued at $3,918,816. The disclosure for this sale can be found here. Over the last three months, insiders sold 483,954 shares of company stock valued at $19,960,682. Company insiders own 3.95% of the company’s stock.

Teladoc Company Profile

Teladoc, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

Institutional Ownership by Quarter for Teladoc (NYSE:TDOC)

Leave a Reply

Your email address will not be published. Required fields are marked *